Evidence map›Paper›PMID 38695021›Full record

ArticleFrontiers in medicine2024

Development, assessment and educational impact of a blended e-learning training program on pharmacovigilance implemented in four African countries.

Francesco Schievano, Kissa W Mwamwitwa, Seth Kisenge, Elice Mmari, Alemayehu Duga, Siphesihle Nhlabatsi, Cassandra Elagbaje, Abiodun Sadikat Abiola, Solomon Getnet Meshesha, Silvia Pagani and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Online Outcomes of a Pediatric Neuro-Oncology Course for Multidisciplinary Healthcare Professionals in Low- and Middle-Income Countries.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 7 countries.

Francesco SchievanoSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Kissa W MwamwitwaSection of Clinical Trials Control and Pharmacovigilance, Tanzania Medicines and Medical Devices Authority (TMDA), Dar es Salaam, Tanzania.
Seth KisengeSection of Clinical Trials Control and Pharmacovigilance, Tanzania Medicines and Medical Devices Authority (TMDA), Dar es Salaam, Tanzania.
Elice MmariKNCV Tuberculosis Foundation, Dar es Salaam, Tanzania.
Alemayehu DugaDoctoral School Societies, Politics, Public Health, Pharmacoepidemiology and Pharmacovigilance, University of Bordeaux, Bordeaux, France.
Siphesihle NhlabatsiNational Pharmacovigilance Center, Eswatini Ministry of Health, Mbabane, Eswatini.
Cassandra ElagbajeKNCV Tuberculosis Foundation, Abuja, Nigeria.
Abiodun Sadikat AbiolaNational Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria.
Solomon Getnet MesheshaArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Silvia PaganiUnit of Medicine, Hospital of Vimercate, Vimercate, Italy.
Riccardo LoraMedBrains, Department of Computer Science, University of Verona, Verona, Italy.
Alberto SabainiMedBrains, Department of Computer Science, University of Verona, Verona, Italy.
Frank CobelensDepartment of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Linda HärmarkNetherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands.
Eric Battey EkoSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Anita ConfortiSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Mauro VenegoniSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Lara MagroSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Ugo MorettiSection of Pharmacology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
University of Verona · ITTanzania Food and Nutrition Center · TZAmsterdam Institute for Global Health and Development · NLArmauer Hansen Research Institute · ETAzienda Ospedaliera di Desio e Vimercate · ITCaritas Nigeria · NGElizabeth Glaser Pediatric AIDS Foundation · TZMinistry of Health · SZNational Agency for the Control of AIDS · NGNetherlands Pharmacovigilance Centre Lareb · NLUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Efforts to improve medication access in low-and middle-income countries, particularly in Sub-Saharan Africa, have made progress, especially in the fight against infectious diseases such as tuberculosis. However, challenges exist in establishing effective pharmacovigilance systems. The PhArmacoVIgilance Africa (PAVIA) project was committed to enhancing pharmacovigilance in Tanzania, Eswatini, Nigeria, and Ethiopia, with an emphasis on anti-tuberculosis drugs, utilizing various methods, including training. This study evaluates the PAVIA training program's effectiveness and its adaptation during the COVID-19 pandemic. Methods: A blended e-learning program, incorporating two courses and a platform for educational materials, was developed. This program, designed to train healthcare professionals in pharmacovigilance, was incorporated into a Training of Trainers model. To evaluate the program effectiveness, we used multiple measures such as assessing knowledge gain through pre-and post-test scores, assessing learners' satisfaction and attitudes via questionnaires, and analyzing Individual Case Safety Reports (ICSRs) in VigiBase to determine the impact on spontaneous reporting systems in the PAVIA countries. Results: 121 learners enrolled in the pilot trainings, including 36 from Tanzania, 34 from Eswatini, 25 from Nigeria, and 26 from Ethiopia. Notably, post-test scores were significantly higher than pre-test scores in all four countries. Following the pilot trainings, multiple step-down training sessions were held in Tanzania, Eswatini, and Nigeria, with a total of 827 learners registering and 421 successfully completing the program. Learners' scores on the post-tests were significantly higher than on the pre-tests for both courses in all three countries. Learners' feedback on the training was overwhelmingly positive. Additionally, a qualitative analysis of ICSRs revealed a substantial increase in reports after the training in Tanzania, Eswatini, and Nigeria. Discussion: An innovative e-learning program trained healthcare professionals in pharmacovigilance and anti-tuberculosis drug safety over 3 years in four PAVIA countries. The program effectively improved participants' knowledge, received positive feedback, and likely had an impact on reporting rates in Tanzania, Eswatini, and Nigeria, although a direct causal link could not be definitively established due to data limitations and other factors, such as the heightened reporting rates associated with COVID-19 vaccines, that could have contributed to the notable increase in ICSRs.

Indexed as

Africablended-learningcascade trainingpharmacovigilancetuberculosis

Identifiers

PMID38695021
PMCPMC11061462
OpenAlexW4394888200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.